Skip to main content

Table 4 Adverse events by treatment groups

From: A novel food-based negative oral contrast agent compared with two conventional oral contrast agents in abdominal CT: a three-arm parallel blinded randomised controlled single-centre trial

Type of adverse event Lumentin 44 (n = 18) Omnipaque (n = 12) MoviPrep (n = 14)
Adverse events (n) Patients, n (%) Adverse events (n) Patients, n (%) Adverse events (n) Patients, n (%)
Gastrointestinal disorders 10 7 (38.9) 13 7 (58.3) 14 8 (57.1)
 Abdominal distension 1 1 (5.6) 1 1 (8.3) 1 1 (7.1)
 Epigastralgia 1 1 (5.6) 3 3 (25.0) 3 3 (21.4)
 Diarrhoea 0 0 (0.0) 3 3 (25.0) 6 6 (42.9)
 Eructation 1 1 (5.6) 0 0 (0.0) 0  
 Flatulence 4 4 (22.2) 4 4 (33.3) 3 3 (21.4)
 Nausea 2 2 (11.1) 2 2 (16.7) 1 1 (7.1)
Rectal haemorrhage 1 1 (5.6) 0 0 (0.0) 0 0 (0.0)
General disorder, chills 0 0 (0.0) 1 1 (8.3) 0 0 (0.0)